Global Neurological Biomarkers Market to Reach $19.96 Billion by 2029, Growing at 14% CAGR

What combination of drivers is leading to accelerated growth in the neurological biomarkers market?
The escalating instances of brain-related conditions are projected to bolster the progression of the neurological biomarker market in future. Diseases affecting the brain, spine and other nerves of the body fall under neurological ailments. The nerves also have control over certain parts of the body, and Parkinson's disease is one such neurodegenerative condition that affects these areas. Neurological biomarkers facilitate an early detection of Parkinson's disease through pathological, genetic, and biochemical assessment. For example, the Parkinson's Foundation, a non-profit organization based in the US, revealed in December 2022, that there was a significant increase in the new cases of Parkinson's disease in 2022, with 90,000 diagnoses as compared to 60,000 annually in 2021. Therefore, the rising frequency of such neurological disorders fuels the expansion of the neurological biomarker market.

Get Your Neurological Biomarkers Market Report Here:
https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

What is the projected compound annual growth rate (CAGR) of the neurological biomarkers market from 2025 to 2034, and what factors influence it?
In recent years, the neurological biomarkers market has seen a swift expansion. The market, which was worth $10.7 billion in 2024, is expected to rise to $11.96 billion in 2025, signifying an 11.7% compound annual growth rate (CAGR). Several factors contributed to this increase during the historic period, such as the rising occurrence of neurological conditions, an aging population, the requirement for drug development, increased investments in neurological research, and the emergence of personalized medicine.

The market size for neurological biomarkers is projected to witness significant expansion in the upcoming years, reaching $19.96 billion by 2029 with a compound annual growth rate (CAGR) of 13.7%. The anticipated growth during this period is associated with factors such as early detection biomarkers, biosensors, wearable technology, global health drives, and patient-centric strategies. Key trends forecasted for the said period include advancements in imaging technology, the fast-paced development in omics technologies, the inclusion of artificial intelligence (AI), the application of real-world evidence in biomarker verification, progressive diagnostic technologies, along with increased partnership between industry and research institutes.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12677&type=smp

How are the latest trends influencing the growth of the neurological biomarkers market?
Leading businesses engaged in the neurological biomarkers market are developing strategic alliances to introduce innovative products and bolster their foothold in the industry. Such collaborations in the neurological biomarkers landscape stimulate ingenuity, optimize mutual proficiencies, and expedite the creation and commercial rollout of progressive therapies by merging resources and capabilities. For example, in July 2022, NeuroSense Therapeutics Ltd., hailing from Israel, which specializes in therapies for severe neurodegenerative diseases, entered into a partnership with NeuraLight, another Israeli company known for developing sensitive and objective biomarkers for neurological ailments. The mutual effort aims to pinpoint oculometric markers for Amyotrophic Lateral Sclerosis (ALS) by using the power of Artificial Intelligence (AI) and Machine Learning (ML). Introduced following NeuraLight's successful $25 million Series A funding, the alliance aims to amplify the detection and use of ALS digital markers in a concurrent study. This constitutes the first clinical trial of this partnership. The emphasis of the partnership lies on the use of oculometric digital markers, which could potentially enable patient categorization and enhance success rates in clinical trials.

What are the major segments of the neurological biomarkers market and their role in driving growth?
The neurological biomarkers market covered in this report is segmented -

1) By Product: Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Other Products
2) By Application: Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Schizophrenia, Depression, Multiple Sclerosis, Spinal Muscular Atrophy
3) By End-User: Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, Other End-Users

Subsegments:
1) By Proteomics Biomarker: Protein Biomarkers, Antibody Biomarkers
2) By Genomics Biomarker: DNA Biomarkers, RNA Biomarkers
3) By Metabolomics Biomarker: Metabolite Biomarkers, Lipid Biomarkers
4) By Imaging Biomarker: MRI Biomarkers, PET Scan Biomarkers
5) By Other Products: Neuroinflammatory Biomarkers, Neurotransmitter Biomarkers

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12677

Which regions are key players in the growth of the neurological biomarkers market?
North America was the largest region in the neurological biomarkers market in 2024. The regions covered in the neurological biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the key firms paving the way for growth in the neurological biomarkers market?
Major companies operating in the neurological biomarkers market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12677&type=smp

What Is Covered In The Neurological Biomarkers Global Market Report?

• Market Size Forecast: Examine the neurological biomarkers market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the neurological biomarkers market for a structured understanding.
• Key Players Overview: Analyze major players in the neurological biomarkers market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the neurological biomarkers market.
• Segment Contributions: Evaluate how different segments drive overall growth in the neurological biomarkers market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the neurological biomarkers market.
• Industry Challenges: Identify potential risks and obstacles affecting the neurological biomarkers market.
• Competitive Landscape: Review strategic developments in the neurological biomarkers market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.